Radium-223

Radium-223
Name	Radium-223
Mass number	223
Category	Radioisotope
Discovered	1898
Decay mode	Alpha decay
Half life	11.4 days

Radium-223 Radium-223 is a radioactive isotope used predominantly in medicine and studied across physics, chemistry, and environmental science. It links the historical work of Marie Curie, the development of nuclear physics in the early 20th century, and contemporary therapies emerging from institutions like Memorial Sloan Kettering Cancer Center and Mayo Clinic. Research on Radium-223 involves collaborations among laboratories such as Lawrence Berkeley National Laboratory, Oak Ridge National Laboratory, and pharmaceutical companies including Algeta and Bayer.

Introduction

Radium-223 occupies a niche at the intersection of radiochemistry, oncology, and nuclear engineering, following in the legacy of Pierre Curie, Ernest Rutherford, and Frederick Soddy. Its study benefited from techniques developed at Cavendish Laboratory, Institut du Radium, and later at national facilities like Brookhaven National Laboratory and Los Alamos National Laboratory. Clinical translation involved trials at centers such as Johns Hopkins Hospital and Royal Marsden Hospital.

Physical and Nuclear Properties

Radium-223 is an alpha-emitting radionuclide with a mass number 223 and a measured half-life of about 11.4 days, determined using methods refined at European Organization for Nuclear Research and National Institute of Standards and Technology. Its decay chain includes short-lived daughters whose emissions have been characterized in studies associated with International Atomic Energy Agency standards and measurements at National Physical Laboratory. Nuclear data for Radium-223 are cataloged alongside isotopes studied in facilities like Argonne National Laboratory and summarized in compilations from International Union of Pure and Applied Chemistry.

Production and Isolation

Production routes for Radium-223 include neutron irradiation of actinium or radium targets in research reactors such as High Flux Isotope Reactor and accelerator-driven methods developed at TRIUMF and Paul Scherrer Institute. Chemical isolation techniques evolved from radiochemical separations pioneered at Institut Laue–Langevin and use ion-exchange, solvent extraction, and chromatographic methods standardized by groups at Centre National de la Recherche Scientifique and Korea Institute of Radiological and Medical Sciences. Supply chains for clinical-grade material often involve license-holding organizations regulated by agencies like U.S. Nuclear Regulatory Commission and European Medicines Agency.

Medical Applications

Radium-223 is approved for targeted treatment of bone metastases and has been evaluated in randomized trials conducted at institutions including University College London, University of Texas MD Anderson Cancer Center, and Vall d'Hebron Institute of Oncology. Clinical endpoints and protocols referenced guidance from groups such as European Society for Medical Oncology and American Society of Clinical Oncology. Oncology research involving Radium-223 interfaced with therapeutic strategies at centers like Dana–Farber Cancer Institute and combinatorial trials with agents developed by Pfizer and Novartis.

Mechanism of Action and Pharmacokinetics

Radium-223 mimics calcium, localizing to areas of increased bone turnover as observed in preclinical studies at Salk Institute and Fred Hutchinson Cancer Center. Its alpha emissions deliver high linear energy transfer over short ranges, a property characterized in experiments at Lawrence Livermore National Laboratory and modeled using tools from European Centre for Nuclear Research. Pharmacokinetic studies performed at Vanderbilt University Medical Center and Karolinska Institutet report rapid blood clearance and skeletal uptake patterns that informed dosing regimens developed with oversight from Food and Drug Administration and clinical trial sites such as Royal Infirmary of Edinburgh.

Safety, Dosimetry, and Radiation Protection

Dosimetry for Radium-223 is calculated using frameworks from International Commission on Radiological Protection and measurement techniques refined at National Physical Laboratory. Radiation safety practices align with protocols from Occupational Safety and Health Administration and training at Centers for Disease Control and Prevention. Hospital handling and waste management follow guidance from World Health Organization and national regulatory bodies including Health Canada and Agence nationale de sécurité du médicament et des produits de santé.

Environmental Fate and Regulation

Environmental monitoring of Radium isotopes draws on methods used in studies by United Nations Scientific Committee on the Effects of Atomic Radiation and long-term assessments performed near sites like Chernobyl Nuclear Power Plant and Hanford Site. Regulatory frameworks governing release, transport, and disposal involve agencies such as Environmental Protection Agency and European Commission directorates. Remediation techniques for radium-contaminated sites have been developed in projects led by Sandia National Laboratories and multinational collaborations coordinated through Organisation for Economic Co-operation and Development.

Category:Radioisotopes